• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Metabolism
    • Anti-infectives
    • Cancer
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Euronext Growth
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
February 05, 2018

Tim McCarthy, Chairman of Immupharma discusses the completion of Lupuzor™ pivotal phase III study and initiation of follow up study.

Read More
January 15, 2018

Small Company Share Watch – Jan 2018…

Read More
October 04, 2017

Q&A with Tim McCarthy Non-Executive Chairman at ImmuPharma PLC (LON:IMM)

Read More
September 28, 2017

On the right track – Sept 2017

Read More
May 30, 2017

Business insights from Small Cap Leaders – May 2017

Read More
April 13, 2017

Why Lupus Treatment is a potential game-changer – April 2017

Read More
April 10, 2017

All Street Cap – April 2017

Read More
August 25, 2016

Healthcare Heroes – Shares magazine, August 2016

Read More
July 07, 2016

Northland Capital Partners ImmuPharma Initiation VA – July 2016

Read More
July 01, 2016

AIM Journal – July 2016

Read More
June 08, 2016

Lupus news today – June 2016

Read More
March 08, 2016

Growth Company Investor – March 2016

Read More
  • 1
  • 2
  • 3
  • 4
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved

Cookies

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy